A B S T R A n . Early-onset neonatal group B 8-hemoljtic streptococcus (GBS) infection exhibits pathophysiologic characteristics of a toxic shock syndrome, in which a cascade of inflammatory mediators are involved. 'Illromboxane 1 1 2 (TSA2) is thought to play an important role as a mediator of the pulmonary response to GBS toxin, because high lung lymph concentrations of a'l'SA2 metabolite have been observed after GUS toxin injections in sheep. The aim of this study was to evaluate the effects of a selective antagonist of the 'I'SA2-prostaglandin endoperoxide receptor (SQ 29, 548) . Six unanesthetized young lambs, each serving a s its own control, were given S Q 29,548 or vehicle control followed by GBS toxin challenge. Ifemodynamic and lung function (lung mechanics, lung volume, ventilation) responses were followed for 5 11. When compared with the control studies, treatment with S Q 29,548 significantly altered the response to GBS toxin. S Q 29,548 reduced the increase in pulmonary and systemic vascular resistance, improved cardiac output and stroke volume, improved dynamic lung compliance but not airway resistance, and improved oxygenation. l'he attenuating effect of S Q 29,548 was most pronounced during the first phase of toxin response (15-90 min after toxin infusion), but significant treatment effects were also seen during the second phase (120-300 min after toxin infusion). 'l'llis study demonstrates that 'I'SA2 is an important mediator of the response to GBS toxin and is responsible for hemodynamic and lung function changes. Thrombosane receptor blockade may offer a potential therapeutic approach to infants with severe early-onset GBS sepsis. (Pediatr Res 35: 571-579, 1994) PG, prostaglandin PI.,,, left atrial pressure pulmonary arterial pressure I'VR, pulmonary vascular resistance R,, lung resistance TS. tlirombosane Early-onset infection by GBS in thc ncwborn infant is still a potentially lifc-threatening condition with high mortality (I). This discasc is characterizcd by scverc respiratory distress, pulmonary hypcrtcnsion, lung injury with incrcasc in pulmonary capillary pernleability, lung edema, progressive respiratory failure, circulatory collapse, and dcath (2, 3). Early-onset GBS infection exhibits pathophysiologic characteristics of a toxcmic shock syndromc, in which a cascade of different inflammatory mcdiators such as prostaglandins, platclct-activating factor, protease, oxygcn radicals, and cytokincs arc engaged (4) . An cxotoxin from culture mcdium ofGBS type 111 obtaincd from infants with carly-onset GBS infcction has bccn isolatcd and charactcrizcd as the agent primarily involved in this condition ( 5 , 6 ) . GBS toxin is a polysaccharide with an approximate molecular mass of 200 000 D. Previous studies have suggcstcd that mannosyl phosphodicster groups constitute functionally active sites on tlic toxin and that, whcn injectcd into shcep, GBS toxin accumulated prcdominately in thc lung (7) . Intravenous infusion of picomole amounts of GBS toxin has bccn shown to induce inflammation also in tumor ncovasculaturc in micc, which likc humans are susceptible to GBS as nconatcs (8) .
Thc isolation of the GBS toxin has madc it possible to dcvclop an animal model to study the pathophysiologic events in this discasc. This has previously bccn donc by our group in both shccp (9. 10) and young lambs (2. 10-12) . A biphasic rcsponsc to the toxin has bccn found. During thc first phasc, thcrc is increased lung resistance, decreased dynamic lung compliance, incrcascd ventilation, hypoxcmia, pulmonary hypcrtcnsion, and fever. The second phasc is characterizcd by less prominent changes in thesc variables together with increascd lung lymph protein clearance compatible with incrcascd vascular pcrmcability. An increase in lung lymph concentration of TXBZ. which is a stable metabolite of TXA:, coincidcs with the first phasc of thc toxin rcaction (13, 14) . Prcvcnting TXAZ formation by indomcthacin abolished pulmonary hypcrtcnsion during the first phasc, implying that TXAZ might be one of the mcdiators responsible for the scvcrc hcmodynamic and lung function changcs sccn in the GBS toxic shock syndromc (13) .
The advantage of using a bolus injection of GBS toxin as donc in our lamb model is that it makes it possible to better study thc diffcrcnt pathophysiologic components participating in thc GBS sepsis reaction. In fulminant human sepsis or in animal models using infusion of GBS bacteria, all these pathophysiologic events are going on at the same time, because it can be suspected that there is a continuous production of toxin by the GBS bacteria.
The aims of this study were to perform a comprehensive determination of the role of TXAz as a mediator of the GBS toxin response and to test the potential pharmacologic effects of a selective antagonist of the TXA2-prostaglandin endopcroxide receptor, ( IS-[I (u,2P(5Z),3P,4a] (15) , during GBS toxin challenge in the unanesthetized young lamb model. The study was designed to investigate the interrelationship between ventilatory and circulatory pathophysiology leading to respiratory insufficiency in GBS sepsis in a way not previously done.
MATERIALS AND METHODS
rltiit~ialprcparatioti. Six full-term lambs were instrumented 1 to 2 wk after birth. Polyvinylchloride catheters (1.0 m m inner diameter, 1.8 m m outer diameter) were placed in a femoral artery and a tarsal vein. A catheter was also placed in the right atrium via the right brachial vein for measurement of CVP. Through a left thoracotomy, catheters were inserted directly into the main pulmonary artery and left atrium, and a n electromagnetic flow cuff (C and C Instruments, Culver City, CA) for measurement of C O was placed around the main pulmonary artery. The lambs were then allowed t o recover for an average of 3 to 4 d, after which two pleural balloons (Silastic envelopes) for measurement of pleural pressure were placed in the right pleural space through a small thoracotomy. A tracheostomy was pcrformed and a Swan-Ganz sheath was placed in an external jugular vein. After the operations, all lambs received gentamicin (6 mg/kg/d) and carbenicillin (150 mg/kg/d) during the whole study period. Lambs were allowed to recover for 3 to 4 d before the first study was performed. The second study was performed 4 to 5 d later.
The (17) and newborn infants (18) . The computerized system for calculation of lung mechanics has previously been described in detail (19, 20) . FRC was calculated by dividing the expired lung nitrogen volume by the end tidal nitrogen concentration before the initiation of oxygen breathing. FRC was normalized to body weight. From the nitrogen lung volume elimination curve, a dilution factor that made it possible to estimate ventilatory dead space and alveolar ventilation could be derived. A lung model was used to describe the nitrogen elimination pattern (distribution of ventilation) by fitting one, or the sum oftwo or three, exponential equations to the lung nitrogen elimination curve (21) . The number of equations giving the best least-square fit to the original washout curve was chosen as the best description of the nitrogen elimination pattern (distribution of ventilation). Not all nitrogen washout curves could be satisfactorily described by this exponential lung model, such as when the exponential estimate deviated too much from the original lung nitrogen elimination curve.
The gas mixing efficiency of the ventilatory system was calculated as an NC index. N C index was defined as the ventilatory volume necessary to dilute the nitrogen lung volume from 90 to 10% of its total value, divided by the FRC.
Luboratorj~ atiuij~sis. Arterial blood gas determinations were made using a model 158 pH/blood gas analyzer (Ciba Corning TX agonist. Before each study was completed, the efficacy of SQ 29,548 as a T X receptor antagonist was tested by an i.v. injection of the T X agonist 9,ll-dideoxy-11n,9n-epoxymethano-PGF2, (U 46,619, Upjohn Company, Kalamazoo, MI) in a dose of 5 pg/kg. An average increase in PpA of 2.5 m m Hg occurred when the agonist was given during SQ 29,548 treatment, whereas a n average increase in PpA of 54 m m Hg was observed in the control study.
lsolated eDct of SQ 29,549. The isolated effect of SQ 29, 548 on all physiologic variables was tested in three separate lambs that were 18 to 25 d old. These lambs were instrumented in the same way as those included in the study. We found n o isolated effect by SQ 29,548 on any of the measured variables during a 6-h study period, preceded by 2-h baseline measurements, except for a marginal decline in total PVR. Statistics. We assessed the effect of SQ 29,548 within a period by using a repeated measures analysis of variance when all data were available. The repeated measures analysis of variance combines all data for a period into a single statistical test of the effect of treatment in a period. When some data were missing, we averaged the difference between SQ 29,548 and control for each time available for an animal and then tested whether this average difference was significantly different from zero. This is algebraically equivalent to the test used in the repeated measures analysis of variance when data are complete. Repeated measures analysis of variance was used to determine overall treatment effect during the whole 5-h study period and during each phase of the GBS toxin reaction separately.
T o show how results changed from baseline within a treatment arm or between groups at a single time point, we used paired t tests and show these results in the figures and tables. The results of these tests are intended to help clarify when differences between groups are most pronounced. The results of the individual tests at specific time points are not used in determining whether there is a n overall difference between the two treatment arms.
We claim a n overall treatment effect only if repeated measures analysis of variance (or the equivalent single test of treatment effect when data were incomplete) showed a statistically significant difference at p < 0.05 for the whole 5-h study period. A significant effect in an individual phase ofthe GBS toxin response is based on the repeated measures analysis of variance (or cquivalent test) for that phase.
RESULTS
Bipl~asic rcspotisc. In general, the vascular changes after GBS toxin infusion showed a biphasic response where the phases showed different characteristics. The first phase of the reaction (0.25 to 1.5 h) reached its peak 30 to 60 min after the beginning of toxin infusion. The second phase of the reaction (2 to 5 h) reached its maximum after 2 to 3 hours. PE,, PC,,; a t~d PL, (Fig. I) . PpA and Pew in the control study showed a typical biphasic response with a significant increase in pressure compared with baseline. The first phase showed the highest pressure increase but with shorter duration compared with the second phase. There was a significant overall treatment effect by SQ 29,548 during the whole study period ( p < Ifcart rutc, CO, atid stroh-c vollr~)ic (Fig. 2) . There was no overall treatment effect on heart rate during the study on the basis of the repeated measures analysis of variance. However, in the control study the animals showed a significant increase in heart rate late in the first phase and during the second phase of the reaction. whereas after SQ 29,548 treatment the animals responded sooner with modest tachycardia during both the first and second phase of the toxin reaction. C O decreased significantly compared with baseline 45 min after the beginning of the toxin infusion and remained significantly decreased until after 3 h in the control study. After SQ 29,548 treatment, the animals not only managed to preserve their C O but also showed a significant increase during the first phase of the reaction. The overall treatment effect on C O by SQ 26,548 during the whole TlME AFTER GBS TOXIN (h) phase. No major changes were seen in CVP. Only at 30 min after the start of the toxin infusion was the CVP significantly higher in the control study compared with the SQ 29,548 study.
Systemic vascular resistance increased significantly in the control study but not after SQ 29,548 treatment. The two studies were significantly different in the first phase ( p < 0.05). PVR (Fig. 4) . The major treatment effects of SQ 29,548 were seen on the PVR. In the control study, total PVR significantly increased compared with baseline during both the first and second phase of the reaction. The increase in resistance was higher with shorter duration during the first phase compared with the second phase. Although PVR also increased with SQ 29,548, the increase was later and much smaller and there was a n overall treatment effect of SQ 29.548 ( p < 0.05) during the whole study period, mainly because of a highly significant treatment effect during the first phase of the reaction ( p < 0.01; second phase, p > 0.1). The PVR increase during the first phase of the toxin reaction was abolished by the treatment.
A significant increase compared with baseline in PVR was found on both sides ofthe capillary bed in the lung in the control study. The major PVR change was in the arterial part of the pulmonary circulation, but there were also increases on the venous side. Treatment with SQ 29.548 substantially altered PVR on both sides of the capillary bed, but the treatment effect was statistically significant only in the precapillary bed ( p < 0.05 overall, p < 0.01 in phase 1). The major effect was during the first phase of the reaction that was completely blunted.
Llrr~g mechanics (Fig. 5) . After GBS toxin infusion in the control study, there was a significant decrease in Cd),, compared with baseline during the first phase of the reaction. This decrease in Cdbn coincided with the increase in PpA and PVR. After SQ 29.548 trcatment, no significant changes in C',,, were observed.
There was a significant overall treatment effect ( p < 0.05) by the blocker mainly because of the difference in the first phase ( p < 0.05: second phase, p > 0.1). Calculations of specific compliance (Cd,./FRC) also showed that SQ 29.548 completely blocked the reaction by the toxin during the first phase (data not shown). No significant respiratory rate dependence on the measurements of CdYn could be found.
The changes in RI showed a biphasic response with significant increase compared with baseline in RI during both the first and second phase in the control study. After SQ 29,548 treatment, the changes in RI persisted but to a lesser extent. However, there was no statistical evidence that SQ 29,548 affected RI response after GBS toxin. Calculations of specific conductance ( I . R,-'. FRC-I) did not reveal a statistically significant treatment effect by SQ 29,548 on the airway reactivity to GBS toxin infusion (data not shown).
F R C (Fig. 5 ). No significant difference was found in FRC between the treatment and control studies. A tendency toward an increase in FRC during the study comparcd with baseline was found after SQ 29,548 treatment, whereas after an initial small increase no FRC changes were found in the control study.
I'entilatiotl (Table I ). An increase from baseline in both total and alveolar ventilation (calculated from the nitrogen washout curve) was found in both studies but was more prominent early during the toxin challenge. No trcatment effect by SQ 29,548 was found on ventilation.
Gas mixing efficiency (NC index) was unaffected by GBS toxin infusion both with and without SQ 29,548 treatment. For estimation of the lung nitrogen elimination pattern (distribution of ventilation), a total of 92 curves in the control study and 90 curves in the SQ 29,548 study were subject to description by our exponential lung model (21) . In the control study, 35% of the washout curves could best be described by a single exponential component, and a two-component model fit best in 40% of the curves. In 25% of the curves, exponential estimation of the washout pattern was unsatisfactory according to our lung model. The corresponding numbers in the SQ 29,548 study were 30% (one component), 43% (two components), and 27% (unsatisfactory description). No specific change in exponential patterns could be observed during the course of the studies, and there were no significant differences between the control and SQ 29,548 treatment.
Gas c~.~chrrngc a n d hodv rcr?1perrrtlirc (Tablc 2). There was a significant decrease in oxygenation comparcd with baseline in the control study. There was a much smaller decrease with SQ 29,548 treatment ( p < 0.05 overall). This difference was most pronounced during the first phase of the reaction ( p < 0.01) and -CONTROL cell count after GBS toxin infusion in both studies. Both lymo--+ So 29,548 phocytes and granulocytes were affected. There was a statistically + significant difference in total white blood cell count between the two studies in the sccond phase ( p < 0.05). In the control study.
' some hemoconcentration occurred during both the first and k second phase of the reaction, but a statistically significant difference compared with baseline in packed red cell volume was seen only during the second phase. There was no hemoconcentration during the first phase of the SQ 29,548 studies. ProsturrqIunr/it~s (Tuhle 4). TXBz plasma concentration was significantly increased compared with baseline during the whole + +* study period in both studies. There were no statistically significant differences in serum concentrations whether the animal was of 6-keto-PGF,,, showed a slight increase at I and 2 h after the toxin infusion. There was no significant difference between the B studies.
This study showed that hemodynamic changes dominated after GBS toxin infusion, and these changes were mainly affected by the SQ 29,548 treatment. As has been described previously, the response to GBS toxin was biphasic (10, 11) . In the pulmonary circulation, we found a significant increase in the PpA and PVR in the control study. Treatment of the animal with SQ 29,548 showed a significant treatment effect, abolishing the first phase of the pulmonary vascular reaction. Our results, linking TXAz to pulmonary vasoconstriction during the first phase, support work performed by others (24-3 1) . The second phase of the pulmonary vascular reaction was not significantly attenuated by SQ 29.548 treatment, suggesting that TXAz is mainly involved in the first part of the response. The marked increase in serum concentration of TXB2 during the first phase compared with the sccond phase of the reaction is further support for this idea.
The isolated effect of a prolonged SQ 26,548 infusion was tested in three separate animals. Except for a marginal decline in total PVR, which did not affect the results of the study, we found no isolated effect on any physiologic variable that could be attributcd only to SQ 29, 548 . Also, during baseline measurements before toxin infusion, no effect of SQ 29.548 could be observed. This means that the pathophysiologic differences noted in this study between control and SQ 29,548 treatment are most likely attributed to the effect of SQ 29,548 on changes induced by the GBS toxin rather than a direct effect of SQ 29,548 alone.
In previous histologic examinations of lung tissue after GBS toxin infusion, signs of severe blood congestion have been found (2. 10 ). An increase in the lung microvascular pressure due to venous constriction is the probable cause. We have previously shown that the flow of lung lymph with low protein concentration significantly increases in lambs during the first phase of the GBS toxin reaction (1 1, 12 ). An increase in pulmonary microvascular pressure is clearly implicated by the increased proteinpoor lymph flow rate during the first phase of the reaction. This incrcase in pulmonary microvascular pressure could be caused by an increase in pulmonary venous constriction. This has been extensively studied in the sheep model after E. coli endotoxin challenge (32) . In that study, the fraction of the PVR attributcd to the pulmonary veins was significantly increased during the toxin reaction. In our study, we also partitioned the response in PVR into precapillary and postcapillary compartments, which was not done previously in the GBS model. In the control study, the fraction of the total PVR, which could be attributed to an incrcase in venous constriction, was between 25 and 30% during both the first and second phase of the reaction, whereas the baseline value was about 15% of total PVR. This indicates that pulmonary venous tone is increased during the GBS toxin reaction. The increase in the fraction of the total PVR attributed to the venous side of the lung circulation was abolished during the first phase ofthe reaction during SQ 29,548 treatment. SQ 29,548 treatment may therefore reduce blood congestion of the lung and reduce hemoconcentration, which also occurs in the GBS toxic shock syndrome.
After toxin infusion in the control study, there was a significant decrease in CO, which was caused by a significant reduction in stroke volume. The mechanism behind the cardiac decompensation in the control study could be secondary to hypovolemia and venous pooling, increased afterload, or a direct toxic effect on the myocardium mediated by TXA2 (33) . Treatment with SQ 29,548 preserved stroke volume during the whole study together with CO. The increased C O during the first phase of the GBS toxin response during SQ 29,548 treatment may have been related to increased body temperature and absence of an increase in systemic vascular resistance.
During the control study, lung mechanics showed a marked decrease in Cdyn during the first phase of the toxin reaction coinciding with the increase in PVR. No significant changes in CdYn were found after SQ 29,548 treatment. It is plausible that the main cause of the reduced Cdyn during the first phase of the control study was interstitial edema and blood congestion due to pulmonary venous constriction and a n increase in lung microvascular pressure. It is also plausible that SQ 29.548 prevented pulmonary blood congestion by reducing the pulmonary venous constriction, which improved the mechanical properties of the lung. The improved lung function due to SQ 29,548 treatment during the first phase of the reaction also resulted in significantly better oxygenation compared with that in the control study.
Other factors such as changes in lung volume and respiratory rate could explain a reduction of Cdrn in the control study. However, FRC did not decrease and specific compliance (CdJ FRC) also showed a reduction during the first phase in the control study (data not shown). Uneven distribution of ventilation in combination with a n increase in respiratory rate might cause a decrease in Cdyn. This is probably not the case here, because we found no change in the distribution of ventilation according to our lung model and n o significant correlation between respiratory rate and decrease in Cdrn in either study. Furthermore, the NC index, which is supposed to reflect the gas mixing efficiency and the conditions in the small airways (34, 35), was not affected during either the control or the SQ 29,548 study; this favors uncompromised patency of alveoli and peripheral airways.
In this study, we also found a biphasic increase in resistance to ventilatory flow similar to what we found in a previous study (1 1). Even if there was an attenuation of RI after SQ 29,548 treatment, this effect was not statistically significant. This means that TXAz is not the only mediator of the smooth muscle constriction of the proximal airways. In this study, the proximal airway constriction with increased RI seemed to have little or no influence on ventilation, because FRC and gas mixing efficiency (as judged by the NC index) were unaffected in both studies. Total ventilation and alveolar ventilation, however, were increased both in the control study and after SQ 29,548 treatment. This probably reflects the increased metabolic demand at increased body temperature induced by the GBS toxin infusion.
During the second phase of the reaction, we found a significantly smaller decrease in total white blood cell count during the SQ 29,548 study compared with the control study, which could indicate reduced sequestration of white blood cells in the lung (10) . SQ treatment may therefore also indirectly attenuate granulocyte-mediated lung injury ( 12) .
In conclusion, treatment with a selective antagonist of the TXAz-prostaglandin endoperoxide receptor (SQ 29,548) in the GBS toxin lamb model primarily blocked the pathophysiologic changes during the first phase of the toxin reaction, demonstrating that TXAz is an important mediator ofthat phase. SQ 29,548 treatment led to significant reduction in the changes in pulmonary and systemic vascular resistance, improved C O and stroke volume, improved dynamic lung compliance, and improved oxygenation. T X receptor antagonists, such as SQ 29,548, may offer a potential therapeutic approach to infants with severe early-onset GBS sepsis. We propose that this should be investigated in animal models and humans with ongoing GBS sepsis.
